英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
cephus查看　cephus　在百度字典中的解释百度英翻中〔查看〕
cephus查看　cephus　在Google字典中的解释Google英翻中〔查看〕
cephus查看　cephus　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Decoding cost-effectiveness of PNH therapies - American Society of . . .
    One way for clinicians to do this is to actively advocate for access to cost-effective therapies within their practices’ pharmacy formularies and make informed treatment choices that consider both patient outcomes and the financial sustainability of the health care system
  • Cost to Treat Newly Diagnosed Patients with Paroxysmal Nocturnal . . .
    Given the evolving treatment landscape and challenges in treatment and diagnosis, it is unclear what the total and setting-specific costs and health care utilization are among patients newly diagnosed with PNH
  • Disease-modifying treatments in paroxysmal nocturnal . . . - Springer
    Considering the high economic burden of PNH control and management, as well as the recently approved but high costs of DMTs, this study aims to review the cost-effectiveness of FDA-approved DMTs for PNH systematically
  • Paroxysmal Nocturnal Hemoglobinuria Drug Market -
    Pricing of complement inhibitors for PNH varies widely between developed and emerging markets, reflecting differing economic realities and healthcare infrastructures
  • Cost Utilization Analysis in PNH Treatment Pathways - AJMC
    Carlos M De Castro, MD: The cost utilization study looked at health care costs associated with PNH [paroxysmal nocturnal hemoglobinuria] It was a retrospective They used a claims database to
  • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market
    North America dominates the global PNH treatment market due to the rise in the number of blood bone marrow related diseases, availability of satisfactory reimbursement policies, and increase in awareness about the early diagnosis of the disease in the region
  • Key Findings - ICER
    The discussion during the public meeting highlighted the impact of high costs associated with C5 inhibitors - the current standard of care for PNH - on accessibility and affordability, and its effect on the pricing of new PNH therapies ”
  • Iptacopan and Danicopan for Paroxysmal Nocturnal Hemoglobinuria - ICER
    The value of novel PNH therapies should not be determined exclusively by estimates of long-term cost offsets used in traditional cost-effectiveness analyses alone since the existing standard of care, C5 inhibitors, are priced significantly higher than cost-effective levels
  • Cost per responder analysis of iptacopan versus eculizumab and . . .
    Conclusion: Among both C5i-experienced and complement-inhibitor-naïve patients, treatment with iptacopan resulted in higher response rates and lower cost per responder compared to C5is Paroxysmal nocturnal hemoglobinuria (PNH) is a genetic, progressive bone marrow failure disorder
  • Patient Chart Audit Reveals Changing Paroxysmal Nocturnal . . .
    The study reveals that patient reluctance, along with cost-related barriers—particularly those tied to payer restrictions—are the primary reasons for this gap in treatment Looking ahead, the anticipated introduction of biosimilar eculizumab in 2025 has the potential to shift the PNH market





中文字典-英文字典  2005-2009